PNN DigitalPNN Digital
    Facebook Twitter Instagram
    Sunday, February 15
    Trending
    • The History and Evolution of Valentine’s Day: From Martyrdom To Modern Romance
    • Startup India Fund of Funds 2.0: A Powerful ₹10,000 Cr Reset
    • China’s Zero-Tariff Gate to Africa: A Strategic Awakening Call for India
    • Gen Z Valentine Economy: 1 Generation, Many Industries Winning Big
    • NIS Management Limited Reports Q3 FY26 Revenue of Rs 103.77 Cr; 9M Revenue Stands at Rs 318.66 Cr
    • Exide Empowers Future Engineers
    • Mega ResoFast 2026 – Top 100 Achievers Awarded Tablets by Resonance
    • Varvee Global Limited (VGL) Reports Positive Q3FY26 Growth: Triple-Digit Revenue Gains and 85 Percent 9M Gross Margins
    Submit News
    PNN DigitalPNN Digital
    pnn
    • Home
    • Editor’s Pick
    • Business
    • Entertainment
    • National
    • Lifestyle
    • Technology
    • More
      • Sports
      • Health
      • Finance
      • Education
    PNN DigitalPNN Digital
    Home»Business

    Medico Remedies Announces Robust Financial Performance For Q2 FY 2024

    Medico Remedies Reports Strong Financial Growth in Q2 FY2024, Reinforcing Its Industry Leadership
    Naquiyah MaimoonNaquiyah Maimoon Business 2 Mins Read
    Medico
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Mumbai (Maharashtra) [India], December 24: Medico Remedies Limited, a trusted name in the pharmaceutical industry, announced robust financial financial performance for the quarter ended September 2024.

    Medico Remedies registered a total income of Rs. 400.27 million for the second quarter and a net profit of Rs. 15.56 million. The company’s EPS for the quarter stood at Rs. 0.19, while profit before tax was Rs. 21.32 million. The operating profit margin and net profit margin for the quarter were 7.86% and 3.95% respectively.

    Haresh Mehta, Chairman of Medico Remedies Limited, said, “We are pleased with our financial results for the second quarter. Despite challenging market conditions, we have managed strong revenue and profit performance. We are well-positioned to benefit from the opportunities the fast-growing pharmaceuticals business offers and are confident of improving our financial performance in the coming quarters.”

    Medico

    Medico Remedies is focused on expanding its market presence and is actively pursuing growth opportunities within the sector. It remains committed to providing high-quality medicines and healthcare solutions at affordable prices.

    Headquartered in Mumbai, Medico Remedies is a leading player in the pharmaceutical sector with manufacturing and marketing capabilities in formulation with a focus on anti-infective, beta-lactams, cephalosporins, antimalarial, antiretroviral, anti-ulcer drugs and antacids, vitamins, haematinics and other supplements.

    Medico Remedies also has manufacturing capabilities in other drugs such as NSAIDs, antihistaminics, anti-diabetics, cardiovascular drugs, diuretics, anti-epileptics, combination drug kits, syrups, creams and gels for various therapeutic segments. Established in 1994, the company is known for its commitment to innovation, quality assurance and customer satisfaction.

    Medico

    Medico Remedies’ market cap stood at Rs. 424.55 crore as of Monday, December 23. The company’s shares closed at Rs. 51.16 on the BSE.

    If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.

    Financial Performance Medico Remedies Q2 FY 2024 Robust Financial
    Naquiyah Maimoon

    I dwell in the in-betweens—never sure, never boisterous. Hesitant and obstinate, I see what I'm doing through to completion in ways that never map it out. As a writer, I embrace the grey and the neglected. Nature grounds me, words define me, and I've made peace with being slightly out of step.

    Keep Reading

    Gen Z Valentine Economy: 1 Generation, Many Industries Winning Big

    NIS Management Limited Reports Q3 FY26 Revenue of Rs 103.77 Cr; 9M Revenue Stands at Rs 318.66 Cr

    Exide Empowers Future Engineers

    Varvee Global Limited (VGL) Reports Positive Q3FY26 Growth: Triple-Digit Revenue Gains and 85 Percent 9M Gross Margins

    IIT-Bombay Startup Infiheal Launches DuoChat, World’s First AI Relationship Coach

    Rishab Agarwal’s Petition Challenging WeWork India IPO Disclosures Withdrawn Unconditionally

    pnn
    Recent Posts
    • The History and Evolution of Valentine’s Day: From Martyrdom To Modern Romance
    • Startup India Fund of Funds 2.0: A Powerful ₹10,000 Cr Reset
    • China’s Zero-Tariff Gate to Africa: A Strategic Awakening Call for India
    • Gen Z Valentine Economy: 1 Generation, Many Industries Winning Big
    • NIS Management Limited Reports Q3 FY26 Revenue of Rs 103.77 Cr; 9M Revenue Stands at Rs 318.66 Cr

    The History and Evolution of Valentine’s Day: From Martyrdom To Modern Romance

    14/02/2026

    Startup India Fund of Funds 2.0: A Powerful ₹10,000 Cr Reset

    14/02/2026

    China’s Zero-Tariff Gate to Africa: A Strategic Awakening Call for India

    14/02/2026

    Gen Z Valentine Economy: 1 Generation, Many Industries Winning Big

    14/02/2026

    NIS Management Limited Reports Q3 FY26 Revenue of Rs 103.77 Cr; 9M Revenue Stands at Rs 318.66 Cr

    14/02/2026

    Exide Empowers Future Engineers

    14/02/2026
    Facebook Instagram Twitter
    • Legal Disclaimer
    • Privacy Policy
    • Contact Us
    • About Us
    © 2026 PNN Digital. Designed by Primex Media Services.

    Type above and press Enter to search. Press Esc to cancel.